MilliporeSigma Neuroscience Discovery Grant Program

Published: May 24, 2017

Billerica, Massachusetts, May 24, 2017 – MilliporeSigma has announced a new grant program for graduate students in the U.S. and Canada performing innovative research in neuroinflammation and neurodegenerative disease areas. Four finalists will receive $1,000 grant awards, and one top finalist will receive a $5,000 grand prize. The deadline to enter is June 30, 2017.

Program focus:

· Neuroinflammation and neurodegenerative disease

Submission materials:

· A curriculum vitae summarizing education, work experience, all publications and external presentations, relevant skills and interests, and leadership activities.

· An essay (maximum 400 words) on the participant‘s view of the biggest technical and scientific challenges of current research in understanding neuroinflammation and neurodegenerative disease.

· An application statement (maximum 800 words) summarizing the context, relevance and impact of the participant‘s research in and connection to neuroinflammation and neurodegenerative disease and future research directions.

· A recommendation letter from the participant‘s advisor discussing what makes the participant stand out and why he/she should be considered as a finalist for the program.

· A completed Neuroscience Discovery Award application available at


· To be eligible, a participant must be (i) a current graduate student (Ph.D. or Masters) enrolled for at least two years at, or a graduate student (Ph.D. or Masters) recently graduated from, a university or research institution located in the United States or Canada whose graduation date is between December 1, 2016, and December 31, 2018, and (ii) conducting research in neuroscience.

· Limited to the first 100 applicants.

Find official award information and full rules at

If you are interested in hearing about the finalists or learning more about our neuroscience network of discovery, join our contact list at ( .

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany, completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in health care, life science and performance materials. The company has six businesses—Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials—and generated sales of €15 billion in 2016. More than 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany, is the world’s oldest pharmaceutical and chemical company—since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the U.S. and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Back to news